Sino Biopharmaceutical (HK:1177) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sino Biopharmaceutical has announced that its Eribulin Mesilate Injection has been approved by China’s National Medical Products Administration for treating advanced breast cancer. This approval marks one of the first three such injections sanctioned in China, highlighting the company’s strong R&D capabilities. With several promising drugs in the pipeline, Sino Biopharmaceutical is positioning itself as a leader in breast cancer treatment innovation.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.